Rockefeller Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.74K Buy
208
+8
+4% +$475 ﹤0.01% 4261
2026
Q2
$12.1K Hold
200
– – ﹤0.01% 3938
2026
Q1
$11.6K Sell
200
-900
-82% -$41.5K ﹤0.01% 3933
2025
Q4
$49.3K Buy
1,100
+900
+450% +$37.8K ﹤0.01% 3079
2025
Q3
$8.03K Buy
+200
New +$7.04K ﹤0.01% 3734

Other funds holding XENE

Rockefeller Capital Management's XENE Position: Q3 2026 in Review

Rockefeller Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 4% in Q3 2026, buying an estimated $475 and bringing the position to 208 shares worth $7.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4261.

Rockefeller Capital Management first reported a position in XENE in Q3 2025 and has held it in 5 quarters since. The position peaked at $49.3K in Q4 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Rockefeller Capital Management held 208 shares of Xenon Pharmaceuticals worth $7.74K as of Q3 2026.
  • Rockefeller Capital Management bought 8 Xenon Pharmaceuticals shares in Q3 2026, an estimated $475.
  • Xenon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4261 holding.
  • Rockefeller Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Xenon Pharmaceuticals position peaked at $49.3K in Q4 2025.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.